Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent

Zhang, Wenjia; Liang, Xiaolong; Zhang, Xinyu; Tong, Wei; Shi, Guangyuan; Guo, Haozhuo; Jin, Zhengyu; Tian, Jie; Du, Yang; Xue, Huadan

doi:10.1007/s00259-024-06617-w

Cited by 2 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, molecular imaging, − particularly near-infrared (NIR) fluorescence imaging, − has emerged as a superior alternative. This innovative approach offers noninvasive, real-time visualization of PD-L1 dynamics across entire tumor landscapes. − NIR imaging, especially the second (NIR-II) window, allows for greater tissue penetration and less autofluorescence, resulting in improved detection of PD-L1 expression with increased accuracy and sensitivity .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment

Zhang,

Wang,

Shi

et al. 2024

Bioconjugate Chem.

Self Cite

View full text Add to dashboard Cite

The innovative PD-1/PD-L1 pathway strategy is gaining significant traction in cancer therapeutics. However, fluctuating response rates of 20−40% to PD-1/PD-L1 inhibitors, coupled with the risk of hyperprogression after immunotherapy, underscore the need for accurate patient selection and the identification of more beneficiaries. Molecular imaging, specifically near-infrared (NIR) fluorescence imaging, is a valuable alternative for real-time, noninvasive visualization of dynamic PD-L1 expression in vivo. This research introduces AUNP-12, a novel PD-L1-targeting peptide antagonist conjugated with Cy5.5 and CH1055 for first (NIR-I) and second near-infrared (NIR-II) imaging. These probes have proven to be effective in mapping PD-L1 expression across various mouse tumor models, offering insights into tumor-immune interactions. This study highlights the potential of AUNP-12-Cy5.5 and AUNP-12-CH1055 for guiding clinical immunotherapy through precise patient stratification and dynamic monitoring, supporting the shift toward molecular imaging for personalized cancer care.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In this context, molecular imaging, 25 − 27 particularly near-infrared (NIR) fluorescence imaging, 28 − 31 has emerged as a superior alternative. This innovative approach offers noninvasive, real-time visualization of PD-L1 dynamics across entire tumor landscapes.…”

Section: Introductionmentioning

confidence: 99%